CagriSema
Combination of Cagrilintide and Semaglutide for enhanced weight management
Clinical Research Score: 4/5 — Backed by Phase 3 clinical trials combining cagrilintide and semaglutide for obesity; under regulatory review, not yet approved.
Categories: Weight Loss / Metabolic
What is CagriSema?
CagriSema is the strategic combination that Novo Nordisk developed to push weight loss results even further than semaglutide alone. By combining semaglutide (GLP-1 agonist) with cagrilintide (amylin analog) in a single weekly injection, it attacks appetite through two completely different pathways.
Phase 3 trials showed up to 25% body weight reduction — numbers that rival even retatrutide. People describe the appetite suppression as more complete and more comfortable than either peptide alone. Cravings are quieter. Fullness comes earlier and lasts longer. The nausea that sometimes accompanies GLP-1 medications may actually be reduced by the complementary amylin pathway.
What makes CagriSema particularly practical is the single-injection convenience. Instead of managing two separate peptides, dosing schedules, and injection sites, you get both compounds in one weekly shot. For people who have had good results with semaglutide but want to push further, or for those just starting and wanting the most comprehensive approach, CagriSema represents a well-researched, convenient, and powerful option.
How CagriSema works
CagriSema works through dual-pathway activation. Semaglutide activates GLP-1 receptors to suppress appetite, improve insulin secretion, and slow gastric emptying. Cagrilintide activates amylin receptors to provide additional, complementary satiety signals and further slow stomach emptying through a different mechanism. Because these two pathways are independent and complementary, the combined appetite suppression is greater than either alone — and the side effect profile may actually be smoother because the body receives two moderate signals rather than one intense one.
Scientific overview
CagriSema is a co-formulated combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) in a single subcutaneous injection. By targeting both amylin and GLP-1 pathways simultaneously, CagriSema provides complementary mechanisms of appetite suppression and metabolic regulation. Phase 3 trials have shown superior weight loss compared to either component alone, with up to 25% mean body weight reduction.
Dosing
- Starting dose: 0.25 mg/0.25 mg per week
- Common dosage range: Titrated up to 2.4 mg cagrilintide / 2.4 mg semaglutide per week
- Administration: Subcutaneous
- Half-life: ~7 days (both components)
- Frequency: Once weekly